Introduction
group of post-menopausal women with a previous history of kidney stones with age-and post-menopausal time-matched normal controls [5] . The women with Nephrolithiasis is a common clinical disorder affecting previous kidney stones had significantly less bone 1-5% of the general population, with an annual incidmineral density at both cortical and trabecular sites. ence of 0.1-0.3% [1] . Excessive calcium excretion
To assess whether diminished bone mass would represents the major pathophysiological cause of already be present during early stages of the disease, kidney stones. Most of the series have shown that we analysed the bone mineral density of hypercalciuric almost half of the patients with renal stones had children and normal controls, matched for gender, age idiopathic hypercalciuria as the primary metabolic and height. The hypercalciuric children demonstrated alteration [2] .
lower trabecular bone mineral density than controls The excessive urinary calcium excretion, the fact [6 ] . The potential impact of these findings on final that some of these patients have excessive intestinal peak bone mass, a major determinant of adult bone calcium absorption and the knowledge that the majormass, needs to be evaluated further prospectively. ity of the stones are composed of different forms of calcium crystals, have led to a customary dietary calcium restriction. This nutritional indication has been Hypercalciuria, cause or consequence? suggested by the majority of physicians, independently of the cause of the kidney stones. However, this At this point, a question remains to be answered: is calcium restriction has not prevented kidney stone hypercalciuria the result of a primary disorder of bone recurrence; on the contrary, it might have increased metabolism, or is the decrease in bone mineralization their incidence [3] . At the same time, calcium restric-a consequence of the negative calcium balance induced tion can induce a situation of persistent negative cal-by hypercalciuria? cium balance, with potential damage to another organ:
Studies by Pacifici et al. demonstrated that monothe bone.
cytes from patients with fasting hypercalciuria had an increased production of interleukin-1 (IL-1), a potent in vivo and in vitro stimulator of bone resorption [7] .
Bone mineral in hypercalciuria
These findings were not present in patients with absorptive hypercalciuria. These observations led us to Decreased bone mineral density has been reported in examine further whether a specific fraction of the IL-1 different series of patients with nephrolithiasis using (a or b) or other cytokines involved in bone resorption, different techniques, such as single or dual photon, such as IL-6 or tumour necrosis factor-a ( TNF-a), X-ray and computerized tomography absorptiometry, may play a role in the bone resorption of hypercalciuria radiological evaluation or in vivo neutron activation [8] . We examined a group of patients with recurrent analysis. Bone histomorphometric studies in hypercal-renal stones with and without hypercalciuria, and ciuric patients have yielded controversial results. Some normal controls matched for age, height and weight. have reported increased osteoclastic resorption accom-The hypercalciuric subjects showed statistically significant lower trabecular ( lumbar spine) bone mineral Correspondence and offprint requests to: José R. Weisinger, Servicio density than the normocalciuric or control subjects 
Role of the diet and the acid load
Another factor to be considered, potentially leading to increased bone turnover, consists of subtle metabolic acidosis, as a result of high dietary protein intake. This condition could lead to the release of calcium salts from bone, as calcium carbonate acts as a buffer [9] . The oral administration of potassium bicarbonate, at a dose sufficient to neutralize endogenous acid, improves calcium and phosphorus balance and reduced bone resorption in post-menopausal women [10] . The efficacy of this therapeutic manoeuvre in patients with hypercalciuria remains to be evaluated. Fig. 1 . Bone mineral density determined at trabecular bone ( lumbar Genetics spine), in normal subjects and renal stone formers with and without hypercalciuria. Bone mineral density is expressed as g/cm2.
We already know that idiopathic hypercalciuria can be genetically determined, and there is a known increase patients with absorptive or fasting hypercalciuria. At in intestinal vitamin D receptor number in hypercalcithe same time, we found a significant correlation uric rats. Recently, Morrison et al. suggested that bone between in vitro IL-1a production in unstimulated mass, a main determinant of osteoporotic fracture, has cultures and the Z-score of the lumbar spine mineral a genetic component ascribed largely to a simple allelic content, indicating that enhanced IL-1a production change in the vitamin D receptor gene [11] . These correlates with the degree of demineralization in the authors demonstrated that monozygotic twins show hypercalciuric subjects. We subsequently evaluated less variation in bone mass than dizygotic twins, and lipopolysaccharide (LPS)-induced cytokine production that the main mechanism responsible for this genetic in mononuclear cells obtained from normocalciuric effect is linked to polymorphism of the vitamin D and hypercalciuric stone formers and control subjects. receptor gene. The heredity of hypercalciuria as related There was a significant difference in the observed IL-to the metabolic bone alterations should also be 1a, IL-6 and TNF-a production in the hypercalciuric addressed. In preliminary studies we have demonsubjects compared with normocalciuric stone formers strated that asymptomatic mothers of children with or control subjects. idiopathic hypercalciuria and low bone mass also have In addition, we have found that the expression of decreased bone mineral density at trabecular and IL-1a, IL-6 and TNF-a mRNA, determined by cortical sites. polymerase chain reaction (PCR), are increased in unstimulated blood monocytes obtained from hypercalciuric patients when compared with normal subjects Effect of drugs that inhibit bone resorption (Figure 2 ). These observations suggest that the enhanced cytokine production may be regulated at the In a recent study, we examined the effect of alendrontranscriptional level.
ate, a bisphosphonate that inhibits bone turnover, In summary, these observations demonstrate upon calcium excretion, bone resorption markers and increased in vitro production of various cytokines bone mass. Bisphosphonates are pyrophosphate anainvolved in bone resorption in patients with hyper-logues that bind strongly to the bone mineral, hydroxycalciuria and nephrolithiasis.
apatite. However, the reduced osteoclastic resorption is mainly the result of inhibition of osteoclastic recruitment and osteoclastic activity on the bone surface, and by shortening the osteoclast life span [12] . A group of patients with idiopathic hypercalciuria and recurrent calcium stone formation and age-and gender-matched normocalciuric stone formers received 10 mg per day of alendronate for 1 year. Clinical characteristics, as well as gender and age distribution, were similar in both groups of patients.
It was found that in hypercalciuric subjects, urinary calcium decreased significantly at the end of the first month after alendronate, and remained lower there- after, without reaching normal values ( Table 1) . Total RNA was extracted from unstimulated monocytes obtained Simultaneously, urinary hydroxyproline also decreased from normal controls and hypercalciuric stone formers. Lane 1, IL-significantly after alendronate administration. Serum 1a positive control; lanes 2 and 3, control subjects; lanes 4 and 5, normocalciuric subjects; and lanes 6 and 7 hypercalciuric patients. calcium, glomerular filtration rate and urinary sodium 
